BUFORD, Ga.--(BUSINESS WIRE)--Apr 10, 2013--Theragenics Corporation (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced that Galt Medical (a wholly-owned subsidiary of Theragenics) launched its Torx™ transitionless guidewire line. The Torx™ guidewire uses a proprietary transitionless construction for improved navigation during challenging interventional cases. The Torx™ guidewire has a number of features including a solid Nitinol core which provides flexibility and kink resistance, a Galt Gold™ coiled tip that allows for enhanced visualization, and a coating designed for maximum control and durability throughout the procedure. The Torx™ line of guidewires is available in a variety of diameters, tip lengths, and angles for a wide range of applications. In 2009, IMS Health, a leading provider of information services for the healthcare industry, estimated that the U.S. transitionless guidewire market was $1 million annually with a 30% annual growth rate.
“The Torx™ guidewire is a great addition to Galt’s comprehensive line of guidewires,” said M. Christine Jacobs, Chairman and Chief Executive Officer of Theragenics Corporation. “This product line shows our commitment to providing health care providers with innovative, niche products in growing markets. These types of products will continue to be a focus for us in the future.” Galt Medical, along with NeedleTech Products and CP Medical, comprise Theragenics’ surgical products business segment.
Theragenics Corporation (NYSE: TGX) operates two business segments: its surgical products business and its brachytherapy seed business. The surgical products business ( www.cpmedical.com, www.galtmedical.com, www.needletech.com ) manufactures and distributes wound closure, vascular access, and specialty needle products. Wound closure products include sutures, needles and other surgical products. Vascular access includes introducers, guidewires and related products. Specialty needles include coaxial, biopsy, spinal and disposable veress needles, access trocars, implanters, introducer products, and other needle-based products. The surgical products segment serves a number of markets and applications, including, among other areas, interventional cardiology, interventional radiology, vascular surgery, orthopedics, plastic surgery, dental surgery, urology, veterinary medicine, pain management, endoscopy, and spinal surgery. Theragenics’ brachytherapy business manufactures, custom loads, distributes and markets “seeds” used primarily in the minimally invasive treatment of localized prostate cancer. The Company’s brachytherapy product line ( www.theragenicsbrachy.com ) includes its palladium-103 TheraSeed ® device, its iodine-125 AgX100 ® device and related services. The terms "Company," "we," "us," or "our" mean Theragenics Corporation and all entities included in our consolidated financial statements. For additional information, call our Investor Relations Department at (800) 998-8479 or visit www.theragenics.com.